News | Artificial Intelligence | September 23, 2020

RADLogics FDA Cleared for Novel AI-powered Chest X-ray Application

510(k) clearance for novel AI-Powered chest X-ray application developed to identify and prioritize chest X-ray scans that appear to contain a pneumothorax for urgent radiologist review

RADLogics AI-Powered solution in use: chest X-ray of COVID-19 positive case with heatmap key image.

RADLogics AI-Powered solution in use: chest X-ray of COVID-19 positive case with heatmap key image.

September 23, 2020 — RADLogics announced that the company’s novel AI-powered chest X-ray pneumothorax application has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The clearance paves the way for healthcare providers, hospital networks and clinicians to have access to artificial intelligence (AI) software that is trained via pattern recognition to process chest X-rays and immediately flag scans with a suspected pneumothorax, a collapsed lung, for urgent radiologist review. The application is available immediately through the Nuance AI Marketplace for Diagnostic Imaging.

Operating in parallel with existing workflow, RADLogics’ chest X-ray solution uses an artificial intelligence algorithm to analyze images for features suggestive of pneumothorax. It then makes case-level output available to a PACS workstation for worklist prioritization or triage. The AI-powered solution integrates into a comprehensive, seamless, and secure workflow to augment acute care teams with deep clinical insight and actionable data in minutes. The application was validated and trained by a multi-center study for detecting pneumothorax in hundreds of chest X-rays.

"We are very pleased to receive FDA 510(k) clearance for our AI-Powered chest X-ray pneumothorax application, which adds to our array of AI-Powered solutions for CT and X-ray that are designed to improve efficiency and reduce burnout for radiologists that are under greater pressure than ever before,” said Moshe Becker, CEO and Co-Founder of RADLogics. "From extreme pressure on capacity and resources to a major financial strain due to the ongoing COVID-19 pandemic, there is no question that the healthcare system is in need for new solutions such as AI to augment caregivers to alleviate the increased burden and support better outcomes.”

In accordance with FDA guidance for imaging systems and software to address the COVID-19 public health emergency, RADLogics has made its FDA cleared X-ray and CT solutions available to hospitals and healthcare systems throughout the U.S. for patient triage and management. Designed for easy integration and installation both on-premise and via the cloud – RADLogics’ algorithms are supported by the company’s patented workflow software platform that enables rapid deployment at multiple hospitals, and seamless integration with existing workflows.

To further validate the use of chest X-ray solutions, the company highlighted a new paper in preprint entitled “COVID-19 in CXR: from Detection and Severity Scoring to Patient Disease Monitoring”. Led by Professor Hayit Greenspan from Tel Aviv University and members of the RADLogics’ algorithm development team, the paper studied the severity of pneumonia in COVID-19 patients through a longitudinal study of disease progression. Using a deep learning model for simultaneous detection and segmentation of pneumonia in chest X-ray (CXR) images and generalized to COVID-19 pneumonia, the study found that the measurement of disease severity through a “Pneumonia Ratio” that enabled the research team to build a disease extend profile over time for hospitalized patients.

Results of this study are available on arXiv.org, and it has been submitted to the JBHI IEEE journal for review and potential publication.

Related Content

Videos | Coronavirus (COVID-19) | November 20, 2020
This video shows a computed tomography (CT) scroll through showing bowel ischemia and perforation (see arrows) due to
Single-slice of the chest CT showing the abnormalities. Arrows indicate the location of the breast mass (red arrow), lymphadenopathy (blue arrow), and a lung nodule (yellow arrow). Arrows not present in experimental display. Image courtesy of Psychonomic Bulletin & Review

Single-slice of the chest CT showing the abnormalities. Arrows indicate the location of the breast mass (red arrow), lymphadenopathy (blue arrow), and a lung nodule (yellow arrow). Arrows not present in experimental display. Image courtesy of Psychonomic Bulletin & Review

Feature | Radiology Imaging | November 20, 2020
There’s a classic video demonstrating how our brains process information and allocate attention in which people bounc
Ziehm Imaging will showcase its leading portfolio of mobile C-arms and advanced pre- and intraoperative image-based decision support solutions on its virtual RSNA 2020 booth
News | Mobile C-Arms | November 20, 2020
November 20, 2020 — Ziehm Imaging will showcase its leading portfolio of...
Densitas Inc., a global provider of A.I. technologies for digital mammography and breast screening, announced its partnership with Mammography Educators to offer the first artificial intelligence powered telehealth technologist training platform to support business continuity in mammography facilities.
News | Mammography | November 20, 2020
November 20, 2020 — Densitas Inc., a global provider of A.I.
Chest X-ray image of patient with lung injury due to vaping. Image courtesy of UC Regents #COVID19 #pandemic

Chest X-ray image of patient with lung injury due to vaping. Image courtesy of UC Regents

News | Coronavirus (COVID-19) | November 19, 2020
November 19, 2020 — A UC Davis Health ped